Johnson & Johnson
NYSE:JNJDrug Manufacturers - General
-$4.59 today
- Market cap
- $656.47B
- Beta
- 0.26
- P/E (TTM)
- 26.7
- EPS (TTM)
- $8.60
- Dividend yield
- 2.28%
Volume 7.93M
Average 7.71M
JNJ Long-term Debt
Borrowings due after more than one year.
Johnson & JohnsonNYSE: JNJ
Long-term Debt · Q3 FY2026 · quarter ended Sep 2026
Long-term debt falls 9.2% from a year ago
Long-term debt stood at $35.8B at the end of Q3 FY2026, down 9.2% from a year earlier and down 4.1% from the prior quarter. Over 3 fiscal years it compounded at +13.6% a year.
Context
- Long-term debt amounted to 18.1% of total assets at the end of Q3 FY2026, down 2.3 pp from a year earlier.
- Long-term debt increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether long-term debt keeps falling in the next quarterly balance sheet after a -9.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Long-term Debt history
USD · from the balance sheet
- Latest · FY2025
- 39.44B USD
- Year-over-year change
- +28.7%
- 4-year CAGR
- +7.1%
| Period | Period end | Long-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-28 | 39.44B | +28.7% |
| FY2024 | 2024-12-29 | 30.65B | +18.4% |
| FY2023 | 2023-12-31 | 25.88B | -3.7% |
| FY2022 | 2023-01-01 | 26.89B | -10.3% |
| FY2021 | 2022-01-02 | 29.99B | — |
Long-term Debt vs competitors
How JNJ compares with its peers on the latest reported figures
- Peers report in different currencies, so long-term debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -9.2% is the 10th highest of 11, against a peer median of +6.1%.
- Long-term debt amounts to 18.1% of total assets for JNJ, versus a peer median of 35.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $62.48B USD | -0.8% | +0.3% | 46.2% | |
| Jun 2026 | $60.5B USD | +5.2% | +24.5% | 30.1% | |
| Jun 2026 | $51.86B USD | -3.5% | +10.2% | 54.2% | |
| Jun 2026 | $51.08B USD | +50.4% | +17.6% | 39.4% | |
| Jun 2026 | $42.09B USD | -5.3% | +6.9% | 48.0% | |
| Jun 2026 | $37.49B USD | +66.8% | +13.5% | 30.7% | |
| Sep 2026 | $35.8B USD | -9.2% | +13.6% | 18.1% | |
| Sep 2026 | $26.42B USD | +7.0% | +2.5% | 22.1% | |
| Jun 2026 | $23.83B USD | +7.6% | -1.2% | 48.3% | |
| Jun 2026 | €14.65B EUR | +11.0% | -1.4% | 11.3% | |
| Jun 2026 | £13.86B GBP | -33.9% | -3.2% | 22.6% | |
| Peer median (excluding JNJ) | — | +6.1% | +4.7% | 35.0% | |
Competitors are the stored peer set for JNJ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Jan 2022 | FY2022 Jan 2023 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 14.49B | 12.89B | 21.86B | 24.11B | 19.71B |
| Short-term Investments | 17.12B | 9.39B | 1.07B | 417M | 393M |
| Net Receivables | 18.98B | 16.92B | 14.87B | 18.93B | 17.18B |
| Inventory | 10.39B | 10.27B | 11.18B | 12.44B | 14.19B |
| Other Current Assets | (3.7B) | 5.83B | 0 | 0 | 4.15B |
| Total Current Assets | 60.98B | 55.29B | 53.5B | 55.89B | 55.62B |
| Property, Plant & Equipment (Net) | 18.96B | 17.98B | 19.9B | 20.52B | 23.17B |
| Goodwill | 35.25B | 36.05B | 36.56B | 44.2B | 48.77B |
| Intangible Assets | 46.39B | 38.49B | 34.18B | 37.62B | 50.4B |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 10.22B | 8.95B | 9.28B | 10.46B | 6.87B |
| Other Non-current Assets | 10.22B | 30.62B | 14.15B | 11.41B | 14.37B |
| Total Non-current Assets | 121.04B | 132.08B | 114.06B | 124.21B | 143.59B |
| Total Assets | 182.02B | 187.38B | 167.56B | 180.1B | 199.21B |
| Account Payables | 11.06B | 9.89B | 9.63B | 10.31B | 11.99B |
| Short-term Debt | 3.77B | 12.76B | 3.45B | 5.98B | 8.5B |
| Tax Payables | 1.11B | 2.22B | 2.99B | 3.77B | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 3.59B | 6.64B | 3.99B | 4.13B | 4.53B |
| Total Current Liabilities | 45.23B | 55.8B | 46.28B | 50.32B | 54.13B |
| Long-term Debt | 29.99B | 26.89B | 25.88B | 30.65B | 39.44B |
| Deferred Tax Liabilities | 7.49B | 3.99B | 3.19B | 2.45B | 6.79B |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 25.3B | 23.9B | 23.43B | 25.19B | 17.31B |
| Total Non-current Liabilities | 62.77B | 54.77B | 52.5B | 58.29B | 63.54B |
| Total Liabilities | 108B | 110.57B | 98.78B | 108.61B | 117.67B |
| Common Stock | 3.12B | 3.12B | 3.12B | 3.12B | 3.12B |
| Retained Earnings | 123.06B | 128.35B | 153.84B | 155.79B | 168.98B |
| Accumulated OCI | (13.06B) | (12.97B) | (12.53B) | (11.74B) | (14.93B) |
| Other Stockholders Equity | (123.06B) | (128.35B) | (153.84B) | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 74.02B | 76.8B | 68.77B | 71.49B | 81.54B |
| Total Debt | 33.75B | 39.64B | 29.33B | 36.63B | 47.93B |
| Net Debt | 19.26B | 26.75B | 7.47B | 12.53B | 28.22B |
Johnson & Johnson
NYSE:JNJ
Intrinsic Alpha fair value
Locked
Current Price
$272.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.